Several studies have demonstrated the efficacy of the oral pre-exposure prophylaxis with daily tenofovir plus emtricitabine on preventing HIV negative partners to become infected, and many trials are investigating its role in a real-life setting and different populations. PrEP is already available in the United States, approved by European Medicine Agency, but not available in Italy. In this short review we analyze two different studies carried out in Europe.